SCHEMBL787685

SCHEMBL787685

COC(=O)c1ccc(-c2ncc(Nc3cccc(C(C)C)c3)c3ccccc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.47
KDR P35968 4/20 0.44
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
AKR1C4 P17516 1/20 0.42
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
AKR1C1 Q04828 1/20 0.42
CAMK2D Q13557 1/20 0.42
KDM4E B2RXH2 3/20 0.41
CDC25B P30305 2/20 0.40
PDE5A O76074 2/20 0.40
MAPT P10636 4/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
TP53 P04637 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15052604 0.90 RXRA (0.49) KDRHPGDAKR1C4AKR1C3AKR1C2
SCHEMBL787767 0.83 MAPK1 (0.51) MAPK1KDRAKR1C3AKR1C2MAPT
SCHEMBL787703 0.82 KDR (0.66) KDRMAPTTP53
SCHEMBL787760 0.82 MAPK1 (0.43) MAPK1KDRALDH1A1HPGDSMN1; SMN2
SCHEMBL787470 0.77 KDR (0.52) KDRKDM4EMAPTABCG2ABCB1
SCHEMBL15052558 0.72 KDR (0.61) KDRALDH1A1HPGDSMN1; SMN2KDM4E
SCHEMBL787451 0.71 AURKA (0.51) ALDH1A1SMN1; SMN2AKR1C3AKR1C2MAPT
SCHEMBL18878388 0.71 RXRA (0.69) MAPTNPC1RAB9A
SCHEMBL806103 0.68 KDR (0.78) KDRALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL806125 0.68 KDR (0.72) KDRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616443-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS Exelixis, Inc. (US) 2013-07-24 EP claimed
WO-2012037132-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS EXELIXIS, INC. (US) 2012-03-22 WO claimed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 US disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 US disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 US disclosed
WO-2012037132-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS EXELIXIS, INC. (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165440-A1 JAK1 Inhibitors JAK1, JAK2, JAK3 MAPK1 51/4885KDR 1782/4885ALDH1A1 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.